NME1 functions as a metastasis suppressor in pancreatic cancer

Boissan M, Schlattner U, Lacombe M-L (2018) The NDPK/NME1 superfamily: state of the art. Lab Invest 98(2):164–174 Chin VL, Lim CL (2019) Epithelial-mesenchymal plasticity—engaging stemness in an interplay of phenotypes. Stem Cell Investig 6:25 Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20(2):69–84 Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579):472–476 Huna A, Nawrocki-Raby B, Padilla-Benavides T, Gavard J, Coscoy S, Bernard D, Boissan M (2021) Loss of the metastasis suppressor NME1, but not of its highly related isoform NME1, induces a hybrid epithelial-mesenchymal state in cancer cells. Int J Mole Sci 22(7):3718 Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN, Levine H (2015) Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol 5:155 Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. The Lancet 388(10039):73–85 Kim D, Kim Y, Lee BB, Kim D, Lee OJ, Jeong P, Kim WJ, Cho EY, Han J, Shim YM, Kim DH (2020) Negative effect of reduced NME1 expression on recurrence-free survival in early stage non-small cell lung cancer. J Clin Med 9(10):3067 Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P (2017) The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19(5):518–529 Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196 Liu L, Li M, Zhang C, Zhang J, Li G, Zhang Z, He X, Fan M (2018) Prognostic value and clinicopathologic significance of nm23 in various cancers: a systematic review and meta-analysis. Int J Surg 60:257–265 Maria K, Ruxan L, Gordon B, Bm T, S, Ioannis, K, Z, (2022) Mechanical stress signaling in pancreatic cancer cells triggers p38 MAPK- and JNK- dependent cytoskeleton remodeling and promotes cell migration via Rac1/cdc42/Myosin II. Mol Cancer Res 20(3):485–497 Mátyási B, Farkas Z, Kopper L, Sebestyén A, Boissan M, Mehta A, Takács-Vellai K (2020) The function of NM23-H1/NME1 and its homologs in major processes linked to metastasis. Pathol Oncol Res 26(1):49–61 McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS (2018) Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 24(43):4846 Müller PC, Frey MC, Ruzza CM, Nickel F, Jost C, Gwerder C, Hackert T, Z’graggen K, Kessler U (2021) Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence. Pharmacology 106(3–4):143–153 Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH (2018) Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 15(6):333–348 Pamidimukkala NV, Leonard MK, Snyder D, Mccorkle JR, Kaetzel DM (2018) Metastasis suppressor NME1 directly activates transcription of the ALDOC gene in melanoma cells. Anticancer Res 38(11):6059–6068 Pamidimukkala N, Puts GS, Kathryn Leonard M, Snyder D, Dabernat S, De Fabo EC, Noonan FP, Slominski A, Merlino G, Kaetzel DM (2021) NME1 and NME2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma. Br J Cancer 124(1):161–165 Roberts MR, Sucheston-Campbell LE, Zirpoli GR, Higgins M, Freudenheim JL, Bandera EV, Ambrosone CB, Yao S (2016) Single nucleotide variants in metastasis-related genes are associated with breast cancer risk, by lymph node involvement and estrogen receptor status, in women with European and African ancestry. Mol Carcinog 56(3):1000–1009 Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA A Cancer J Clin 68(1):7–30 Singhi AD, Koay EJ, Chari ST, Maitra A (2019) Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology 156(7):2024–2040 Sterneck E, Poria DK, Balamurugan K (2020) Slug and E-cadherin: stealth accomplices? Front Mol Biosci 7:138 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703 Wang Y, Shi J, Chai K, Ying X, Zhou B (2013) The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets 13(9):963–972 Wang Y, Leonard MK, Snyder DE, Fisher ML, Eckert RL, Kaetzel DM (2019) NME1 drives expansion of melanoma cells with enhanced tumor growth and metastatic properties NME1 and melanoma stem cells. Mol Cancer Res 17(8):1665–1674 Zhang L, Sanagapalli S, Stoita A (2018) Challenges in diagnosis of pancreatic cancer. World J Gastroenterol 24(19):2047 Zhao M, Li Z, Qu H (2015) An evidence-based knowledgebase of metastasis suppressors to identify key pathways relevant to cancer metastasis. Sci Rep 5(1):1–12 Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu C-C, LeBleu VS, Kalluri R (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579):525–530